Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Mar 27;69(12):343-346.
doi: 10.15585/mmwr.mm6912e2.

Severe Outcomes Among Patients With Coronavirus Disease 2019 (COVID-19) - United States, February 12-March 16, 2020

Collaborators, Affiliations
Free article

Severe Outcomes Among Patients With Coronavirus Disease 2019 (COVID-19) - United States, February 12-March 16, 2020

CDC COVID-19 Response Team. MMWR Morb Mortal Wkly Rep. .
Free article

Abstract

Globally, approximately 170,000 confirmed cases of coronavirus disease 2019 (COVID-19) caused by the 2019 novel coronavirus (SARS-CoV-2) have been reported, including an estimated 7,000 deaths in approximately 150 countries (1). On March 11, 2020, the World Health Organization declared the COVID-19 outbreak a pandemic (2). Data from China have indicated that older adults, particularly those with serious underlying health conditions, are at higher risk for severe COVID-19-associated illness and death than are younger persons (3). Although the majority of reported COVID-19 cases in China were mild (81%), approximately 80% of deaths occurred among adults aged ≥60 years; only one (0.1%) death occurred in a person aged ≤19 years (3). In this report, COVID-19 cases in the United States that occurred during February 12-March 16, 2020 and severity of disease (hospitalization, admission to intensive care unit [ICU], and death) were analyzed by age group. As of March 16, a total of 4,226 COVID-19 cases in the United States had been reported to CDC, with multiple cases reported among older adults living in long-term care facilities (4). Overall, 31% of cases, 45% of hospitalizations, 53% of ICU admissions, and 80% of deaths associated with COVID-19 were among adults aged ≥65 years with the highest percentage of severe outcomes among persons aged ≥85 years. In contrast, no ICU admissions or deaths were reported among persons aged ≤19 years. Similar to reports from other countries, this finding suggests that the risk for serious disease and death from COVID-19 is higher in older age groups.

Conflict of interest statement

All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed.

Similar articles

See all similar articles

Cited by 83 articles

  • Interaction of the prototypical α-ketoamide inhibitor with the SARS-CoV-2 main protease active site in silico: Molecular dynamic simulations highlight the stability of the ligand-protein complex.
    Liang J, Pitsillou E, Karagiannis C, Darmawan KK, Ng K, Hung A, Karagiannis TC. Liang J, et al. Comput Biol Chem. 2020 May 28;87:107292. doi: 10.1016/j.compbiolchem.2020.107292. Online ahead of print. Comput Biol Chem. 2020. PMID: 32485652 Free PMC article.
  • Epidemiologic character of COVID-19 in Kazakhstan: A preliminary report.
    Maukayeva S, Karimova S. Maukayeva S, et al. North Clin Istanb. 2020 Apr 14;7(3):210-213. doi: 10.14744/nci.2020.62443. eCollection 2020. North Clin Istanb. 2020. PMID: 32478290 Free PMC article.
  • Intellectual and developmental disability and COVID-19 case-fatality trends: TriNetX analysis.
    Turk MA, Landes SD, Formica MK, Goss KD. Turk MA, et al. Disabil Health J. 2020 May 24:100942. doi: 10.1016/j.dhjo.2020.100942. Online ahead of print. Disabil Health J. 2020. PMID: 32473875 Free PMC article.
  • Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study.
    Kuderer NM, Choueiri TK, Shah DP, Shyr Y, Rubinstein SM, Rivera DR, Shete S, Hsu CY, Desai A, de Lima Lopes G Jr, Grivas P, Painter CA, Peters S, Thompson MA, Bakouny Z, Batist G, Bekaii-Saab T, Bilen MA, Bouganim N, Larroya MB, Castellano D, Del Prete SA, Doroshow DB, Egan PC, Elkrief A, Farmakiotis D, Flora D, Galsky MD, Glover MJ, Griffiths EA, Gulati AP, Gupta S, Hafez N, Halfdanarson TR, Hawley JE, Hsu E, Kasi A, Khaki AR, Lemmon CA, Lewis C, Logan B, Masters T, McKay RR, Mesa RA, Morgans AK, Mulcahy MF, Panagiotou OA, Peddi P, Pennell NA, Reynolds K, Rosen LR, Rosovsky R, Salazar M, Schmidt A, Shah SA, Shaya JA, Steinharter J, Stockerl-Goldstein KE, Subbiah S, Vinh DC, Wehbe FH, Weissmann LB, Wu JT, Wulff-Burchfield E, Xie Z, Yeh A, Yu PP, Zhou AY, Zubiri L, Mishra S, Lyman GH, Rini BI, Warner JL; COVID-19 and Cancer Consortium. Kuderer NM, et al. Lancet. 2020 May 28:S0140-6736(20)31187-9. doi: 10.1016/S0140-6736(20)31187-9. Online ahead of print. Lancet. 2020. PMID: 32473681 Free PMC article.
  • Gaucher disease and SARS-CoV-2 infection: Emerging management challenges.
    Mistry P, Balwani M, Barbouth D, Burrow TA, Ginns EI, Goker-Alpan O, Grabowski GA, Kartha RV, Kishnani PS, Lau H, Lee CU, Lopez G, Maegawa G, Packman S, Prada C, Rosenbloom B, Lal TR, Schiffmann R, Weinreb N, Sidransky E. Mistry P, et al. Mol Genet Metab. 2020 May 11:S1096-7192(20)30116-5. doi: 10.1016/j.ymgme.2020.05.002. Online ahead of print. Mol Genet Metab. 2020. PMID: 32471800 Free PMC article. No abstract available.
See all "Cited by" articles

Supplementary concepts

Feedback